Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 2, 2010, Pages 491-498

  Reding, Kerryn W ^a,b   Bernstein, Jonine L ^c   Langholz, Bryan M ^d   Bernstein, Leslie ^e   Haile, Robert W ^d   Begg, Colin B ^c   Lynch, Charles F ^f   Concannon, Patrick ^g   Borg, Ake ^h   Teraoka, Sharon N ^g   Törngren, Therese ^h   Diep, Anh ^d   Xue, Shanyan ^d   Bertelsen, Lisbeth ⁱ   Liang, Xiaolin ^c   Reiner, Anne S ^c   Capanu, Marinela ^c   Malone, Kathleen E ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

^h LUND UNIVERSITY   (Sweden)

ⁱ INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

Adjuvant therapy; BRCA1; BRCA2; Breast cancer; Chemotherapy; Contralateral; Counter matching; Tamoxifen

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FEMALE; GENE MUTATION; GENETIC CODE; GENETIC SCREENING; HETEROZYGOTE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL RECORD; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DENMARK; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TAMOXIFEN; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77956186324     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0769-3     Document Type: Article

References (32)

1. A Antoniou PD Pharoah S Narod HA Risch JE Eyfjord JL Hopper N Loman H Olsson O Johannsson A Borg B Pasini P Radice S Manoukian DM Eccles N Tang E Olah H Anton-Culver E Warner J Lubinski J Gronwald B Gorski H Tulinius S Thorlacius H Eerola H Nevanlinna K Syrjakoski OP Kallioniemi D Thompson C Evans J Peto F Lalloo DG Evans DF Easton 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 5 1117 1130 10.1086/375033 1:CAS:528:DC%2BD3sXjslagtbg%3D 12677558
2. D Ford DF Easton M Stratton S Narod D Goldgar P Devilee DT Bishop B Weber G Lenoir J Chang-Claude H Sobol MD Teare J Struewing A Arason S Scherneck J Peto TR Rebbeck P Tonin S Neuhausen R Barkardottir J Eyfjord H Lynch BA Ponder SA Gayther M Zelada-Hedman the Breast Cancer Linkage Consortium 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet 62 3 676 689 10.1086/301749 1:CAS:528:DyaK1MXlvFeh 9497246
3. HA Risch JR McLaughlin DE Cole B Rosen L Bradley E Kwan E Jack DJ Vesprini G Kuperstein JL Abrahamson I Fan B Wong SA Narod 2001 Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 3 700 710 10.1086/318787 1:CAS:528:DC%2BD3MXit1aksr8%3D 11179017
4. M Robson P Rajan PP Rosen T Gilewski Y Hirschaut P Pressman B Haas L Norton K Offit 1998 BRCA-associated breast cancer: absence of a characteristic immunophenotype Cancer Res 58 9 1839 1842 1:CAS:528:DyaK1cXislentr4%3D 9581822
5. JP Struewing P Hartge S Wacholder SM Baker M Berlin M McAdams MM Timmerman LC Brody MA Tucker 1997 The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 20 1401 1408 10.1056/NEJM199705153362001 1:STN:280:DyaK2s3nsVShug%3D%3D 9145676
6. E Warner W Foulkes P Goodwin W Meschino J Blondal C Paterson H Ozcelik P Goss D lingham-Hawkins N Hamel PL Di V Contiga C Serruya M Klein R Moslehi J Honeyford A Liede G Glendon JS Brunet S Narod 1999 Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer J Natl Cancer Inst 91 14 1241 1247 10.1093/jnci/91.14.1241 1:CAS:528:DyaK1MXltVOhu7k%3D 10413426
7. CB Begg RW Haile A Borg KE Malone P Concannon DC Thomas B Langholz L Bernstein JH Olsen CF Lynch H nton-Culver M Capanu X Liang AJ Hummer C Sima JL Bernstein 2008 Variation of breast cancer risk among BRCA1/2 carriers JAMA 299 2 194 201 10.1001/jama.2007.55-a 1:CAS:528:DC%2BD1cXlslOrsg%3D%3D 18182601
8. BG Haffty E Harrold AJ Khan P Pathare TE Smith BC Turner PM Glazer B Ward D Carter E Matloff AE Bale M varez-Franco 2002 Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status Lancet 359 9316 1471 1477 10.1016/S0140-6736(02)08434-9 11988246
9. LC Verhoog CT Brekelmans C Seynaeve LM van den Bosch G Dahmen AN van Geel MM Tilanus-Linthorst CC Bartels A Wagner A van den Ouweland P Devilee EJ Meijers-Heijboer JG Klijn 1998 Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 Lancet 351 9099 316 321 10.1016/S0140-6736(97)07065-7 1:STN:280:DyaK1czhsVOiuw%3D%3D 9652611
10. Malone KE, Begg CB, Haile RW, Borg A, Concannon PJ, Xue S, Bernstein L, Langholz B, Capanu M, Reiner A, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Anton-Culver H, The WECARE Study Group, Bernstein JL (2010) A population-based study of the relative and absolute risks of contralateral breast cancer associated with carrying mutation in BRCA1 or BRCA2: results from the WECARE Study. J Clin Oncol (in press)
11. K Metcalfe HT Lynch P Ghadirian N Tung I Olivotto E Warner OI Olopade A Eisen B Weber J McLennan P Sun WD Foulkes SA Narod 2004 Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers J Clin Oncol 22 12 2328 2335 10.1200/JCO.2004.04.033 1:CAS:528:DC%2BD2cXpsVWltbs%3D 15197194
12. LJ Pierce AM Levin TR Rebbeck MA Ben-David E Friedman LJ Solin EE Harris DK Gaffney BG Haffty LA Dawson SA Narod IA Olivotto A Eisen TJ Whelan OI Olopade C Isaacs SD Merajver JS Wong JE Garber BL Weber 2006 Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer J Clin Oncol 24 16 2437 2443 10.1200/JCO.2005.02.7888 16636335
13. LC Verhoog CT Brekelmans C Seynaeve EJ Meijers-Heijboer JG Klijn 2000 Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer Br J Cancer 83 3 384 386 10.1054/bjoc.2000.1239 1:STN:280:DC%2BD3cznt1ahsQ%3D%3D 10917555
14. L Bertelsen L Bernstein JH Olsen L Mellemkjaer RW Haile CF Lynch KE Malone H nton-Culver J Christensen B Langholz DC Thomas CB Begg M Capanu B Ejlertsen M Stovall JD Boice Jr RE Shore JL Bernstein 2008 Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women's environment, cancer and radiation epidemiology study J Natl Cancer Inst 100 1 32 40 10.1093/jnci/djm267 1:CAS:528:DC%2BD1cXlslOqu7o%3D 18159070
15. JL Bernstein WD Thompson N Risch TR Holford 1992 Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer Am J Epidemiol 136 8 925 936 1:STN:280: DyaK3s%2FovFehsw%3D%3D 1456269
16. LS Cook E White SM Schwartz B McKnight JR Daling NS Weiss 1996 A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States) Cancer Causes Control 7 382 390 10.1007/BF00052945 1:STN:280:DyaK28zhslSgsQ%3D%3D 8734833
17. PL Horn WD Thompson 1988 Risk of contralateral breast cancer: associations with factors related to initial breast cancer Am J Epidemiol 128 2 309 323 1:STN:280:DyaL1c3nvFGitQ%3D%3D 3394698
18. J Gronwald N Tung WD Foulkes K Offit R Gershoni M Daly C Kim-Sing H Olsson P Ainsworth A Eisen H Saal E Friedman O Olopade M Osborne J Weitzel H Lynch P Ghadirian J Lubinski P Sun SA Narod 2006 Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update Int J Cancer 118 9 2281 2284 10.1002/ijc.21536 1:CAS:528:DC%2BD28XjsVCgt7Y%3D 16331614
19. SA Narod JS Brunet P Ghadirian M Robson K Heimdal SL Neuhausen D Stoppa-Lyonnet C Lerman B Pasini RP de los B Weber H Lynch 2000 Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group Lancet 356 9245 1876 1881 10.1016/S0140-6736(00)03258-X 1:CAS:528:DC%2BD3cXovFWjsL8%3D 11130383
20. JL Bernstein B Langholz RW Haile L Bernstein DC Thomas M Stovall KE Malone CF Lynch JH Olsen H Anton-Culver RE Shore JD Boice GS Berkowitz RA Gatti SL Teitelbaum SA Smith BS Rosenstein AL Borresen-Dale P Concannon WD Thompson 2004 Study design: evaluating gene-environment interactions in the etiology of breast cancer-the WECARE study Breast Cancer Res 6 3 199 214 10.1186/bcr771
21. B Langholz O Borgan 1995 Counter matching: a stratified nested case-control sampling method Biometrika 82 69 79 10.1093/biomet/82.1.69
22. SM Domchek BL Weber 2006 Clinical management of BRCA1 and BRCA2 mutation carriers Oncogene 25 43 5825 5831 10.1038/sj.onc.1209881 1:CAS:528: DC%2BD28XhtVSgurjK 16998496
23. WD Foulkes 2006 BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis Fam Cancer 5 2 135 142 10.1007/s10689-005-2832-5 1:CAS:528: DC%2BD28XltFWktr8%3D 16736282
24. RD Kennedy JE Quinn PB Mullan PG Johnston DP Harkin 2004 The role of BRCA1 in the cellular response to chemotherapy J Natl Cancer Inst 96 22 1659 1668 10.1093/jnci/djh312 1:CAS:528:DC%2BD2cXhtVSqsrzO 15547178
25. ME Robson 2007 Treatment of hereditary breast cancer Semin Oncol 34 5 384 391 10.1053/j.seminoncol.2007.07.011 1:CAS:528:DC%2BD2sXhtleltrzM 17920892
26. PJ McHugh VJ Spanswick JA Hartley 2001 Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance Lancet Oncol 2 8 483 490 10.1016/S1470-2045(01)00454-5 1:CAS:528:DC%2BD3MXms1ehsrs%3D 11905724
27. PO Chappuis J Goffin N Wong C Perret P Ghadirian PN Tonin WD Foulkes 2002 A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer J Med Genet 39 8 608 610 10.1136/jmg.39.8.608 1:STN:280: DC%2BD38vgvVKrug%3D%3D 12161606
28. T Byrski J Gronwald T Huzarski E Grzybowska M Budryk M Stawicka T Mierzwa M Szwiec R Wisniowski M Siolek SA Narod J Lubinski 2008 Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers Breast Cancer Res Treat 108 2 289 296 10.1007/s10549-007-9600-1 1:CAS:528: DC%2BD1cXitleqsb8%3D 17492376
29. C Eng LC Brody TM Wagner P Devilee J Vijg C Szabo SV Tavtigian KL Nathanson E Ostrander TS Frank 2001 Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1 J Med Genet 38 12 824 833 10.1136/jmg.38.12.824 1:CAS:528:DC%2BD38XltVWmsA%3D%3D 11748305
30. JL Khatcheressian AC Wolff TJ Smith E Grunfeld HB Muss VG Vogel F Halberg MR Somerfield NE Davidson 2006 American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting J Clin Oncol 24 31 5091 5097 10.1200/JCO.2006.08.8575 17033037
31. R Nusbaum C Isaacs 2007 Management updates for women with a BRCA1 or BRCA2 mutation Mol Diagn Ther 11 3 133 144 1:CAS:528:DC%2BD2sXovFWlurg%3D 17570734
32. National Comprehensive Cancer Network (2008) NCCN Clinical Practice Guidelines in Oncology-Breast Cancer [electronic article]. http://www.nccn.org/ professionals/physician-gls/PDF/breastpdf ; V.2.2008